COMPARE · Data as of August 21, 2026
DXCM vs SHC
Verdict: Side-by-side breakdown using the Bull Rankings model. DXCM scored 77.5, SHC scored 68.4 — DXCM leads.
Compare another set
DXCM
DexCom, Inc.
77.5
$92.34 · $34.8B
fundamentals as of
Score gap
9.1
DXCM leads
SHC
Sotera Health Company
68.4
$19.57 · $5.6B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestSHC34.3x
- Fastest growthDXCM+15.5%
- Strongest balance sheetDXCM0.53
- Highest qualityDXCM91 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
DXCM
stronger →← stronger
SHC
91
Qualityreturns · margins · balance sheet
62
89
Growthrevenue & earnings expansion
77
58
Valuevaluation vs sector peers
68
DXCM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
DXCM
SHC
$1.4bC+
FCF
$113mC
+15.5%B+
Rev
+8.1%B
0.53B
D/E
3.41D
36.5xC+
P/E
34.3xC+
1.70C+
PEG
1.31B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DXCM
SHC
64% above
Price vs fair valuelower is cheaper
374% above
~24%/yr
Growth the price implies10-yr FCF · lower = less priced in
~51%/yr
-49%
1-yr DCF upside
-80%
-39%
5-yr DCF upside
-79%
-22%
10-yr DCF upside
-77%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DXCM
Why this score
- Buying back stock
- Durable high returns
SHC
No notable signals flagged.
The companies
DXCMDexCom, Inc.
Why now
Medical Devices · market cap $34.8b. Trading near 52-week high of $92.56 — momentum setup, limited technical margin of safety. Revenue growing +16%, comfortably above the S&P median. 25 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $94.12 (implying +2% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 38% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
SHCSotera Health Company
Why now
Diagnostics & Research · market cap $5.6b. Trading near 52-week high of $19.85 — momentum setup, limited technical margin of safety. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $22.72 (implying +16% upside).
Moat
Net margin 13% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 25% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.41 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Beta 1.77 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DXCM and SHC diverge
On the headline score the gap is 9.1 points in favor of DXCM. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityDXCM 90.6 · SHC 62.0DXCM +28.6
- GrowthDXCM 89.5 · SHC 76.5DXCM +13.0
- ValueDXCM 57.6 · SHC 67.5SHC +9.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.